肺炎疫苗的市场规模:疫苗类型，产品类型，领域，流通管道，各地区，2024年～2031年

2024-2031 年肺炎疫苗市场评估

全世界对肺炎链球菌感染的兴趣日益浓厚，疫苗接种的需求也不断增加。其中包括抗生素抗药性细菌的出现以及更容易患肺炎的人口老化。其次，由于政府加强宣传肺炎链球菌疫苗接种的重要性，尤其是针对儿童和高风险族群，疫苗接种覆盖率显着提高。由于这些原因，肺炎疫苗市场正在蓬勃发展，老牌公司和新进业者都在竞相满足对有效预防日益增长的需求。推动市场扩张，预计2023年市场收入将超过99.3亿美元，2031年将达143亿美元。

研究的另一个目标是增加疫苗覆盖的血清型数量，例如默克最近批准的 21 价 CapVaxib。鼻喷剂是正在研究的新递送技术的一个例子，以提高疫苗的可接受性并增强免疫反应。此外，正在研究增强免疫系统对疫苗接种反应的新佐剂，看看它们是否可以用于开发针对多种呼吸道感染的组合疫苗或提供长期保护。这些进展可能促使未来开发出更实用、更有效的肺炎疫苗。预计未来几年该市场将稳定成长，2024年至2031年复合年增长率约为5.15%。

肺炎疫苗市场定义/概述

肺炎疫苗市场负责预防肺炎球菌（肺炎的主要原因）感染的疫苗的发现、生产和分销。这些疫苗接种是儿童和​​成人免疫方案的一部分，旨在保护老年人和幼儿等弱势群体。由于全球对肺炎球菌感染的认识不断增强、抗生素抗药性的发展以及人口老化，市场的前景一片光明。采用新的传递技术和广泛的保护的免疫接种是推动市场扩张的技术发展的例子。特别是，加上政府鼓励接种疫苗的运动，肺炎疫苗市场可能在未来几年保持健康。

肺炎链球菌疾病负担的增加是否会推动肺炎疫苗市场的成长？

与肺炎球菌疾病、脑膜炎和败血症等肺炎球菌感染相关的发病率和死亡率的增加是推动肺炎疫苗市场成长的主要因素。世界卫生组织 (WHO) 估计，每年有超过 150 万人死亡，尤其是幼儿和老年人等弱势群体，因此采取预防措施至关重要。肺炎疫苗为对抗这一重大疾病负担提供了有力的工具，从而促使疫苗接种工作的增加和疫苗市场的成长。

肺炎链球菌（引起肺炎球菌感染的细菌）抗生素抗药性菌株的增加严重影响了肺炎疫苗市场。当这些抗生素抗药性细菌使目前的治疗无效时，疫苗接种提供了最实用的防御。随着抗生素疗效的减弱，肺炎疫苗市场最终将会发展，疫苗接种将被接受以保护弱势群体，特别是老年人和幼儿。

公共卫生措施和意识的提高正在推动肺炎疫苗市场的发展。公共卫生运动和政府资助的免疫计画有效强调了肺炎球菌疫苗接种的价值，特别是针对老年人和儿童等高风险族群。这促使更多的人接种疫苗，从而立即促使对肺炎疫苗的需求增加，随着医疗机构的宣传努力推动市场成长。

此外，推动肺炎疫苗市场的关键因素之一是强调将肺炎链球菌疫苗接种纳入儿童免疫计画。这种策略有两个优点。首先，它可以特别保护幼儿这群易受肺炎链球菌感染的弱势族群。其次，针对儿童的社区范围内的疫苗接种运动有助于培养群体免疫。一般大众受到这种间接保护的保护，包括那些年龄太大或有潜在健康问题而无法接种疫苗的人。因此，世界各地的儿童免疫接种率不断上升，推动了对肺炎疫苗的需求并扩大了市场。

随着新一代肺炎链球菌疫苗的发现，肺炎疫苗市场预计将大幅扩大。解决肺炎球菌疾病负担的迫切性促使製药公司增加了研发投资。这些努力正在促进具有多重好处的下一代疫苗的开发。下一代疫苗可以透过覆盖更广泛的血清型来提供更多种类肺炎球菌菌株的保护。它还可以延长免疫力的持续时间并减少重复接种疫苗的需要。具有改进能力的下一代免疫接种的到来为政府和医疗保健提供者带来了新的机会。随着研究人员寻求更有效的方法来对抗这种疾病，对这些下一代肺炎疫苗的需求预计将增加并推动整个产业向前发展。

疫苗成本上涨会阻碍肺炎疫苗市场的成长吗？

疫苗成本上涨对肺炎疫苗市场的成长构成重大威胁。新兴市场疫苗接种成本低廉，严重阻碍了肺炎疫苗的市场发展。对许多新兴国家来说，开发、製造和分发这些疫苗的成本令人望而却步。由于将肺炎链球菌疫苗纳入国家免疫规划的能力受到限制，免疫覆盖率受到限制。因此，这些国家的很大一部分人口，特别是老年人和儿童，仍然容易受到肺炎球菌感染。缺乏负担能力是市场扩张的严重障碍，因为世界上很大一部分人口无法负担这些挽救生命的疫苗接种费用。

肺炎疫苗接种成本高昂导致的进入不均和市场饱和可能会阻碍整体市场成长。在富裕国家和私人卫生保健工作者中，轻鬆购买和提供这些疫苗的能力可能更高。然而，这种经济不平等带来了重大挑战。在资金有限的新兴国家，公共措施难以维持。这使得大部分新兴经济体人口，特别是老年人和幼儿等最弱势群体，容易受到不平等市场条件的影响。全球市场的大部分地区接受疫苗接种的能力受到严重限制，导致潜在的接种者未被开发，并阻碍了整体成长。

疫苗接种成本的上升可能会阻碍肺炎链球菌疫苗市场的扩张。由于自付费用，生活在公共医疗保健机会较差的地区的人们可能因费用高昂而不愿接种疫苗。因此，人口疫苗接种率可能会下降。当疫苗接种率较低时，群体免疫是间接保护甚至保护未接种疫苗的人的关键点，很难实现。缺乏群体免疫力使所有公民，包括接种疫苗的人，都容易感染传染病。疫苗接种率低可能会让公共卫生官员不愿意花钱购买整体效益较小的疫苗。

此外，与疫苗开发相关的高昂初始成本可能会阻止新进入者进入肺炎疫苗产业。缺乏竞争会在许多方面抑制创新。首先，从事研发的企业较少，探索的视野和方法较少。这可能会完全阻止新疫苗的开发。其次，由于竞争对手较少，现有公司可能不太可能专注于专门为发展中国家设计的疫苗或强调成本效益的疫苗。因此，创造更容易获得或最先进的免疫接种来满足发展中国家的独特需求并提高全球免疫覆盖率可能会受到阻碍。

此外，取得和实施免疫计画的高昂初始成本也可能影响政策制定者。他们可能没有意识到此类举措的长期好处。接种疫苗的人群中肺炎球菌感染显着减少，减轻了医疗保健系统的经济负担，包括住院和治疗。此外，更健康的劳动力可以支持经济扩张。然而，如果不考虑这些长期利益，决策者将不愿意资助疫苗接种活动。这种缺乏远见可能会造成恶性循环。免疫覆盖率较低导致疾病负担增加，增加了卫生保健系统的负担，最终增加了总成本。这证实了人们最初的看法，即疫苗接种费用昂贵，阻碍了投资并限制了肺炎疫苗市场的扩张。

目录

第1章 全球肺炎疫苗市场:简介

• 市场概要
• 调查范围
• 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

• 资料探勘
• 验证
• 一次采访
• 资料来源一览

第4章 肺炎疫苗的全球市场展望

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力分析

第5章 肺炎疫苗的全球市场:各疫苗类型

• 概要
• 肺炎球菌结合型疫苗
• 肺炎球菌多糖体疫苗

第6章 肺炎疫苗的全球市场:各产品类型

• 概要
• 会议 13
• Synflorix
• Pneumovax 23

第7章 肺炎疫苗的全球市场，各部门

• 概要
• 公共
• 民间

第8章 肺炎疫苗的全球市场:各流通管道

• 概要
• 流通合作伙伴企业
• 非官方机构(NGO)
• 政府机关

第9章 肺炎疫苗的全球市场:各地区

• 概要
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区
  • 南美
  • 中东·非洲

第10章 全球肺炎疫苗市场:竞争情形

• 概要
• 各公司的市场排行榜
• 主要的开发策略

第11章 企业简介

• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi Pasteur
• Serum Institute of India Pvt Ltd.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• CSL Limited
• Bharat Biotech International Limited

第12章 主要发展

• 产品的上市/开发
• 合併和收购
• 事业扩大
• 伙伴关係和合作

第13章 附录

• 相关调查

Pneumonia Vaccine Market Valuation - 2024-2031

The rising concern in pneumococcal infections globally is fueling demand for vaccination. This includes the advent of antibiotic-resistant bacterial strains and an aging population that is more prone to pneumonia. Second, there is a notable increase in vaccination rates due to increased government measures and public awareness campaigns about the significance of pneumococcal immunization, especially for children and high-risk persons. The market for pneumonia vaccinations is booming as a result of these reasons, and both long-standing companies and recent arrivals are fighting to supply the rising need for efficient prophylactics. driving market expansion is predicted to push market sales above USD 9.93 Billion in 2023 and reach USD 14.3 Billion by 2031.

Furthermore, the goal of the research is to increase the number of serotypes that vaccines, such as Merck's recently authorized 21-valent Capvaxive, can cover. Intranasal sprays are one example of a novel delivery technique being investigated to enhance vaccine acceptability and maybe enhance immune response. Additionally, research is being done to see whether new adjuvants, which strengthen the immune system's reaction to the vaccination, can be used to develop combination vaccines that target several respiratory infections or even longer-lasting protection. These developments could lead to the development of more practical and effective pneumonia vaccinations in the future. The market is expected to rise steadily in the coming years to grow at a CAGR of about 5.15% from 2024 to 2031.

Pneumonia Vaccine Market Definition/ Overview

The discovery, manufacturing, and distribution of vaccinations that guard against infection by Streptococcus pneumoniae, a primary cause of pneumonia, are served by the pneumonia vaccine market. These vaccinations are administered as part of childhood and adult immunization regimens in order to safeguard susceptible groups, such as the elderly and small children. Due to expanding global awareness of pneumococcal infections, developing antibiotic resistance, and an aging population, the market's future potential appears bright. New delivery techniques and vaccinations with a wider spectrum of protection are examples of technological developments that should propel market expansion. This will probably result in a healthy market for pneumonia vaccines in the upcoming years, especially when combined with government campaigns encouraging vaccination.

Will the Growing Burden of Pneumococcal Disease Fuel the Growth of the Pneumonia Vaccine Market?

The growing burden of pneumococcal disease is a major driver propelling the pneumonia vaccine market forward, the rising prevalence and mortality associated with pneumococcal infections like pneumonia, meningitis, and sepsis is a major driver for the growth of the pneumonia vaccine market. With the World Health Organization estimating over 1.5 million deaths annually, particularly among vulnerable populations like young children and older adults, the need for preventative measures becomes crucial. Pneumonia vaccines offer a powerful tool to combat this significant disease burden, leading to increased vaccination efforts and market growth for these vaccines.

The market for pneumonia vaccines is significantly influenced by the rise of antibiotic-resistant strains of Streptococcus pneumoniae, the bacteria that causes pneumococcal infections. When current therapies become less effective due to these antibiotic-resistant bacteria, immunization becomes the most practical defense. The market for pneumonia vaccines will eventually develop because of the increasing ineffectiveness of antibiotics, which will also probably increase vaccination acceptance, especially to protect vulnerable groups like elderly people and small children.

Growing public health initiatives and awareness are driving the market for pneumonia vaccines. The value of pneumococcal vaccination is being effectively highlighted by public health campaigns and government-sponsored immunization programs, especially for high-risk populations like the elderly and children. This is incentivizing more people to get vaccinated, which is immediately translating to an increase in demand for pneumonia vaccines and driving market growth, along with advocacy efforts by healthcare organizations.

Furthermore, one of the main factors propelling the pneumonia vaccine market is the emphasis on including pneumococcal vaccinations in childhood immunization programs. This strategy provides two advantages. First and foremost, it specifically shields young children, a vulnerable group that is more susceptible to pneumococcal infections. Second, community-wide immunization campaigns for children aid in the development of herd immunity. The general public is protected by this indirect protection, which also includes people who are too old or have underlying medical issues to receive a vaccination. Because of this, rising children immunization rates around the world are driving up demand for pneumonia vaccines and expanding the market.

The market for pneumonia vaccines is expected to increase significantly due to the discovery of new-generation pneumococcal vaccines. Pharmaceutical companies are investing more in research and development because of the growing urgency to address the burden of pneumococcal illnesses. The development of next-generation vaccinations with various benefits is being facilitated by these initiatives. They might provide protection against a greater variety of pneumococcal strains by providing broader serotype coverage. They might also offer immunity that lasts longer, which would lessen the need for repeated vaccinations. The next generation of vaccinations with improved capabilities coming down the pipeline offers governments and healthcare providers intriguing new opportunities. The demand for these next-generation pneumonia vaccines is anticipated to increase as researchers look for more potent methods to fight this illness, driving the industry as a whole forward.

Will High Vaccine Costs Hinder the Growth of the Pneumonia Vaccine Market?

The high vaccine costs pose a significant threat to the growth of the pneumonia vaccine market, the market expansion for pneumonia vaccines is significantly hampered by the low cost of vaccination in developing nations. For many developing countries, the significant expenses involved in the development, manufacturing, and distribution of these vaccinations make them unaffordable. Widespread vaccination coverage is hampered by this restriction on their capacity to incorporate pneumococcal vaccines into national immunization programs. As a result, a sizable portion of the populace in these nations, especially the elderly and children, are still susceptible to pneumococcal infections. Because a substantial section of the world's population cannot afford these life-saving vaccinations, the lack of affordability poses a serious obstacle to market expansion.

Growth in the market as a whole may be hampered by uneven access and market saturation brought on by the high cost of pneumonia vaccinations. The ability to easily afford and deliver these vaccines may be greater in wealthier nations and among private healthcare practitioners, which could result in market saturation in these areas. But this economic inequality poses a significant challenge. With constrained funding, public initiatives in emerging nations find it difficult to stay up. Due to this, a large portion of the population in developing nations-especially the most vulnerable, such as the elderly and small children-remains unprotected in an unequal market landscape. Large segments of the worldwide market are severely limited in their ability to get vaccines, which impedes overall growth by leaving a bigger pool of prospective recipients untapped.

Elevated vaccination expenses may impede the market expansion for pneumococcal vaccines. Due to out-of-pocket costs, people living in areas with little access to public healthcare may be deterred from getting vaccinated when these vaccinations are pricey. Lower immunization rates among the populace may result from this. Herd immunity, the crucial point at which indirect protection protects even the unvaccinated, is more difficult to attain at lower vaccination rates. All members of the population, including the vaccinated, are more vulnerable to epidemics due to this lack of herd immunity. Because of the low vaccination rates, public health officials could be reluctant to spend money on vaccinations that have a small overall benefit.

Additionally, the substantial initial expenses associated with vaccine development may serve as a deterrent for new entrants into the pneumonia vaccine industry. In numerous ways, this lack of competition can impede innovation. First off, fewer viewpoints and methods are being investigated as there are fewer businesses engaged in research and development. This may completely halt the creation of new vaccinations. Second, if there is little rivalry, established businesses might be less inclined to concentrate on vaccinations that are especially made for developing nations or on cost-effectiveness. This may impede the creation of more accessible or cutting-edge vaccinations that could meet the unique requirements of these areas and raise immunization rates worldwide.

Furthermore, the initial high cost of acquiring and administering immunization programs may influence policymakers. They might not realize the significant long-term advantages that these initiatives provide. Pneumococcal diseases are substantially less common in the population that receive vaccinations, which lowers the financial load on healthcare systems for things like hospital stays and treatments. Furthermore, a healthier workforce can support economic expansion. But if these long-term advantages are not considered, decision-makers can be reluctant to fund immunization campaigns. This lack of vision can result in a vicious cycle. A higher disease load from lower vaccination rates puts more strain on healthcare systems and ultimately raises total expenses. This supports the initial belief that vaccinations are expensive, which discourages investment and limits the expansion of the pneumonia vaccine market.

Category-Wise Acumens

Will Increasing Demand for Pneumococcal Conjugate Vaccine (PCV) Propel the growth of the Pneumonia Vaccine Market?

The increasing demand for Pneumococcal Conjugate Vaccines (PCVs) is a major force propelling the growth of the pneumonia vaccine market, One of the main factors propelling the market expansion for pneumonia vaccines is the increased protection that PCV vaccinations provide for kids. Pneumococcal polysaccharide vaccines (PPSVs) have a significant gap that PCV vaccines are specifically designed to fill. As their immune systems are still maturing, young children's immunological responses against PPSVs could not be as robust and durable. PCVs are conjugated to carrier proteins, which helps them overcome this obstacle. These proteins function as immune system training wheels, improving the immune system's ability to identify and react to pneumococcal bacteria. Better protection for kids during their most susceptible years-when they are most likely to have severe repercussions from pneumococcal infections-will result from this.

The market for pneumonia vaccinations is expanding due in large part to the discovery of more recent PCV vaccines with wider serotype coverage. The bacteria Pneumococcus come in a wide variety of strains, or serotypes. People may be susceptible to infection by other strains if they are only protected against a restricted number of these serotypes by traditional vaccinations. Newer PCV vaccinations, on the other hand, are being developed to provide wider serotype coverage. As a result, they can offer defense against a larger variety of pneumococcal strains, thus enhancing overall protection against pneumococcal illnesses. These new, more thorough PCV vaccines will close a significant gap in the current pneumococcal immunization techniques when they become more widely available and integrated into vaccination programs. This will spur the market for pneumonia vaccinations by increasing demand for these cutting-edge shots.

Children's hospitalizations, pneumonia cases, and pneumococcal infections all significantly decline as a result of PCV immunization campaigns. This means that when PCV vaccinations are added to regular childhood immunization programs, there will be a direct rise in demand for them. Second, the benefits of PCV immunization extend beyond personal health. These vaccines lower the burden on healthcare systems greatly by lowering childhood pneumococcal illnesses. Over time, there are significant cost savings due to a reduction in hospital stays and treatment requirements for certain disorders. This financial gain has the potential to encourage governments and medical facilities to increase their funding for PCV immunization campaigns, which would sustain the market for pneumonia vaccines.

Furthermore, as a result of its direct protection against pneumococcal infections, PCV vaccines are in higher demand as they become an essential component of childhood immunization programs. However, the effects extend beyond personal immunity. Programs for PCV immunization also help the community's herd immunity. Pneumococcal germs circulate less when more youngsters receive vaccinations. Everyone benefits from this indirect protection, even those who are unable to receive vaccinations because of age, health issues, or weakened immune systems, such as the elderly. The community as a whole is shielded from pneumococcal illness by herd immunity, which greatly slows its spread. A positive feedback loop is produced by this. As vaccination rates and herd immunity rise, the overall disease burden falls, further strengthening the case for PCV vaccination and propelling the growth of the pneumonia vaccine market.

Additionally, within the pneumonia vaccine industry, a positive cycle of growth and innovation is being driven by the increasing demand for PCV vaccines. Pharmaceutical companies have a significant incentive to engage in research and development as PCV use rises. This results in a pipeline of even more powerful next-generation PCVs. More serotype coverage may be one of these developments, offering protection against an even greater variety of pneumococcal pathogens. Furthermore, studies are being conducted to create PCVs that would provide immunity for a longer period of time, which would lessen the need for repeated vaccinations. Combination vaccinations that target respiratory disorders in addition to pneumococcus are the most promising developments. This would provide even more all-encompassing protection in a single round of vaccinations. The promise of these innovative vaccines not only fuels market growth by creating demand for new products but also holds the potential to significantly improve preventative measures against pneumococcal and other respiratory diseases in the future.

Will Increasing Usage of Prevnar 13 Drive the Growth of the Pneumonia Vaccine Market?

the increasing usage of Prevnar 13, a prominent pneumococcal conjugate vaccine (PCV) developed by Pfizer, is a significant driver of growth in the pneumonia vaccine market, With its established effectiveness, it maintains its top spot. This indicates that it has a proven track record of successfully guarding against 13 distinct serotypes of Streptococcus pneumoniae, the bacteria that causes pneumonia and other severe pneumococcal infections. Its demonstrated efficacy is vital because it gives public health initiatives and healthcare professionals credibility. Prevnar 13 has therefore been widely incorporated into childhood vaccination programs all around the world. Due to the vaccine's broad adoption, there is a correspondingly high demand, which is driving market expansion. Prevnar 13's success also clears the path for the larger PCV market by proving that this kind of vaccination works to prevent pneumococcal infections.

A significant driving force behind the commercial expansion for pneumonia vaccines is the World Health Organization's (WHO) recommendation that Prevnar 13 be included in childhood immunization programs. The safety and efficacy of this proposal are the two main determinants. With the WHO's endorsement, Prevnar 13's excellent safety profile and demonstrated effectiveness against a variety of pneumococcal strains are reassured to medical professionals and public health initiatives. This boosts self-assurance and encourages broader adoption, especially in developing nations. Prevnar 13 is in high demand as these nations increase the scope of their immunization campaigns. The market for pneumonia vaccines is expanding overall, and this is mostly due to the rising demand in a previously neglected market area. The WHO recommendation creates a ripple effect, driving not only Prevnar 13 adoption but also raising awareness and acceptance of PCV vaccines in general, paving the way for a more robust market in the future.

Additionally, the market for pneumonia vaccines is driven by a positive feedback loop created by the increased usage of Prevnar 13. Prevnar 13 immunization results in a considerable reduction in hospital stays, instances of pneumonia, and pneumococcal infections, particularly in youngsters. This results in a dual advantage. First, by shielding kids from dangerous diseases, it immediately enhances people's health results. Second, Prevnar 13 lessens the overall strain on healthcare systems by preventing certain disorders. Long-term cost reductions from pneumococcal diseases are large when there are fewer hospital admissions and treatment requirements. A sustained growth cycle for the pneumonia vaccine market is created when healthcare providers and policymakers are incentivized to invest more in Prevnar 13 immunization campaigns by these economic benefits.

Furthermore, the benefits of widespread Prevnar 13 immunization extend beyond the vaccine market and have a substantial positive impact on the economy and society. Prevnar 13 directly reduces pneumococcal infections, which in turn results in fewer healthcare expenses. Reduced rates of hospital stays, medication use, and doctor visits are caused by fewer incidences of pneumonia and other pneumococcal infections. The healthcare systems' cost reductions from these Prevnar 13 immunization programs provide a powerful incentive for further investment in the program. Moreover, there is no denying the positive effects a healthier populace has on society. Lower rates of childhood illnesses result in better general health, fewer excuses from school, and maybe a more productive workforce. This establishes a positive feedback loop in which a healthier populace gains from Prevnar 13 and strengthens the economy, which in turn drives more demand for the pneumonia vaccination.

Increasingly pharmaceutical companies are showing a great deal of interest in Prevnar 13, thanks to its established efficacy and dominant market position. This means that there will be more competition and funding for R&D. In order to beat Prevnar 13, companies are working hard to produce next-generation PCVs. It is possible that these developments will result in increased protection against a greater variety of pneumococcal strains through broader serotype coverage. Further work is being done to create PCVs that would provide longer-lasting immunity, which would lessen the need for repeated vaccines. Current innovation promises even more potent future prophylactic measures against pneumococcal illnesses, in addition to expanding the PCV market through new product options. A dynamic environment is created when new and improved PCVs hit the market, encouraging more research and development and advancing the industry as a whole.

Country/Region-wise

Will the Increasing Healthcare Expenditure in North America Drive the Pneumonia Vaccine Market?

The increasing healthcare expenditure in North America is a significant factor propelling the growth of the pneumonia vaccine market in the region, As the focus on preventive care continues to grow in North America, the demand for these vaccines is expected to rise steadily, propelling the overall market forward. especially in light of Prevnar 13. The traditional focus of healthcare was on treating pre-existing conditions, frequently at great expense. But a paradigm change is happening. Healthcare systems are realizing that vaccinations and other preventive interventions are long-term, cost-effective investments. Prevnar 13 vaccines provide a potent instrument in this strategy. They help to avoid major pneumococcal illnesses, which in turn lowers the need for costly hospital stays, treatments, and long-term care. In the long run, this results in significant cost reductions for healthcare systems. The economic advantage of Prevnar 13 and other pneumococcal vaccines, along with the evident public health benefits of decreased illness and enhanced quality of life, make them enticing options in the preventive care arena.

Growing public advocacy and knowledge are driving the North American market for pneumonia vaccines. The market gains from this tendency in two ways. First off, healthcare organizations' educational initiatives and public health campaigns are doing a great job of emphasizing the value of vaccination, especially for high-risk populations like the elderly and immunocompromised people. People are taking a more proactive approach to their health as a result of their increased awareness, actively looking out preventative measures like the Prevnar 13 vaccine. Second, this influence is amplified much more by healthcare groups' advocacy efforts. These organizations directly increase the demand for pneumonia vaccinations within the North American market by encouraging people to get vaccinated and highlighting the possible dangers of pneumococcal illnesses as well as the long-term health advantages. This rise in demand creates a positive feedback loop for the market, as it incentivizes further public awareness campaigns and educational efforts, all contributing to sustained market growth.

In North America, government reimbursement programs are a major factor driving the market for pneumonia vaccines. The expense of recommended immunizations, including pneumococcal vaccines like Prevnar 13, is financially supported by these programs, which are provided by numerous government healthcare initiatives. Many people are relieved of a significant financial burden thanks to this support, especially those who might not have been able to pay for the vaccination otherwise. These initiatives successfully broaden the target audience for pneumonia vaccinations by lowering the cost and increasing accessibility to vaccination. This results in a greater number of individuals receiving vaccinations, which immediately spurs market expansion. Moreover, government compensation schemes not only tackle financial issues but also make a clear statement about the significance of public health. Their endorsement of pneumococcal vaccination encourages a more positive public perception of these vaccines, further propelling market expansion in North America.

Additionally, investment in adult immunization programs is driving a new wave of potential in the pneumonia vaccine industry, which is being driven by North America's aging population. The growing number of people in this demographic group has increased awareness of their susceptibility to pneumococcal infections. Healthcare systems are responding by giving adult immunization programs more importance. A new market segment catering only to the demands of senior citizens is created by this emphasis on protecting them. In this setting, vaccinations such as Pneumovax 23, which provide wider serotype coverage than childhood PCV vaccines, become more significant. In addition to growing the market, the introduction of adult immunization programs ensures a consistent need for vaccinations such as Pneumovax 23. This targeted approach ensures ongoing protection for the elderly population, while simultaneously propelling the overall growth of the pneumonia vaccine market in North America.

Furthermore, because of the high cost of healthcare in North America, the market for pneumonia vaccines is fertile ground for innovation, which feeds a cycle of continual expansion. Pharmaceutical corporations are able to make significant investments in the development of next-generation vaccines due to their financial strength. A fascinating field of study is wider-spectrum PCVs. Compared to the present alternatives, these vaccinations are intended to provide protection against an even greater variety of pneumococcal strains. Furthermore, there is great potential for development into combination vaccinations that target several respiratory disorders. These combination vaccinations may provide more complete protection in a single dose, increasing patient adherence and lowering overall medical expenses. This pipeline of innovative vaccines, driven by North America's investment in R&D, not only stimulates market growth by creating new product opportunities but also holds the potential to significantly improve preventative measures against pneumococcal and other respiratory diseases in the future. This continuous cycle of innovation ensures the pneumonia vaccine market in North America remains at the forefront of preventative healthcare.

Will Rising Disease Burden in Asia-Pacific Drive the Pneumonia Vaccine Market?

The rising disease burden of pneumococcal diseases in the Asia-Pacific region is a significant driver for the pneumonia vaccine market, the market for pneumonia vaccines is expected to increase rapidly due to the increasing prevalence of pneumococcal infections in Asia-Pacific. This area presents a serious public health risk due to the high rates of sepsis, meningitis, and pneumonia. There are two aspects to this increased awareness: the public and healthcare professionals both understand how urgent the problem is. Pneumococcal vaccinations are becoming an increasingly important weapon in the fight against these illnesses, which translates into a spike in demand for efficient prevention measures. Governments and medical establishments are paying attention, stressing how critical it is to implement extensive immunization campaigns to safeguard susceptible groups, such as the elderly and children. As a result, the market for pneumonia vaccines in the Asia-Pacific region is expected to develop significantly due to rising disease rates and the growing demand for efficient prophylactic measures.

The market for pneumonia vaccines is hampered in some regions of Asia-Pacific by worries about affordability, but groups like the Vaccine Alliance, or Gavi, are stepping in to close the gap. Gavi's participation is critical because it understands how important it is to strike a balance between accessibility and affordability. Their efforts center on removing the financial barrier to increase access to pneumococcal vaccinations in underdeveloped nations. This generates a long-term sustainable market in addition to improving public health by guaranteeing increased immunization rates and a healthier populace. Gavi opens the door for greater vaccination uptake by removing barriers related to pricing, which eventually drives growth in the Asia-Pacific pneumonia vaccine market.

The market for pneumonia vaccines is experiencing a perfect storm thanks to the expansion of the healthcare infrastructure in Asia-Pacific and the rising government backing for immunization initiatives. There are two main reasons why this tendency is good. First off, improved access to immunization services in rural regions is a result of greater investment in healthcare infrastructure. More people will be able to benefit from pneumococcal vaccinations because to this expanded reach. Second, a more resilient cold chain system results from significant government backing for immunization programs. The network of refrigerated storage and transportation facilities necessary to preserve the effectiveness of vaccinations is known as a "cold chain." Governments can maximize the effectiveness of vaccinations by ensuring that they are delivered and kept under ideal conditions through the reinforcement of this cold chain infrastructure. As a result of these improvements in access and storage, the market for pneumonia vaccines in Asia-Pacific is well-positioned for significant growth.

There is a huge market potential due to the large population and high prevalence of pneumococcal infections. Pharmaceutical businesses are being drawn to engage in research and development projects that are customized to meet the unique demands of the area. Exciting developments like vaccinations that target the most common pneumococcal strains in Asia-Pacific or more reasonably priced formulations appropriate for the region's poorest nations could result from this regional focus. In addition to meeting unmet medical needs, these regional developments would open up new market opportunities and spur major growth and innovation in the Asia-Pacific pneumonia vaccine market.

Furthermore, by extending childhood immunization programs, the Asia-Pacific region is fighting pneumococcal infections, which is propelling the market for pneumonia vaccines. Pneumococcal conjugate vaccines, or PCVs, are being systematically added to several countries' immunization programs. This guarantees that kids get this vital defense when they are most susceptible, which puts them at risk for major issues. Pneumococcal illness vaccination rates are consequently increasing throughout the region. This immediately contributes to a rise in the need for pneumococcal vaccinations, which drives market expansion in Asia-Pacific. Essentially, nations that prioritize youth immunization with PCVs are protecting their young populations and establishing a stable market for pneumonia vaccines in the area.

Competitive Landscape

The pneumonia vaccine market is a dynamic field with established players like Pfizer and Sanofi Pasteur facing competition from emerging economies like China and India. The race is on to develop next-generation vaccines with broader strain coverage and potentially even combination vaccines targeting multiple respiratory illnesses. This, coupled with increasing government immunization programs and rising awareness in developing countries, is driving market growth.

Some of the prominent players operating in the Pneumonia Vaccine Market include:

Pfizer Inc.

Merck & Co. Inc.

GlaxoSmithKline plc

AstraZeneca plc

Sanofi Pasteur

Serum Institute of India Pvt Ltd.

Abbott Laboratories

Hoffmann-La Roche Ltd.

CSL Limited

Bharat Biotech International Limited

Incheon Vaccine Ltd.

Beijing Minhai Biotechnology Co. Ltd.

Lanzhou Institute of Biological Products Co. Ltd.

Walvax Biotechnology Co. Ltd.

Xiamen Innovax Biotech Co. Ltd.

Dynavax Technologies Corporation

Hirom Abbiotec Co. Ltd.

VaxiBio Inc.

Imugene Limited

Latest Developments

In June 2024, Merck Won US FDA Approval for Capvaxive, a 21-valent pneumococcal vaccine targeting a broader range of strains compared to existing options. This could disrupt the market share currently dominated by Pfizer's Prevnar 20 vaccine. The CDC is expected to decide on recommending Capvaxive for adults over 50 later this month. Merck is aiming for Capvaxive to become the preferred choice due to its wider strain coverage.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL PNEUMONIA VACCINE MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL PNEUMONIA VACCINE MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model

5. GLOBAL PNEUMONIA VACCINE MARKET, BY VACCINE TYPE

• 5.1. Overview
• 5.2 Pneumococcal Conjugate Vaccine
• 5.3 Pneumococcal Polysaccharide Vaccine

6. GLOBAL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE

• 6.1. Overview
• 6.2. Prevnar 13
• 6.3. Synflorix
• 6.4. Pneumovax 23

7. GLOBAL PNEUMONIA VACCINE MARKET, BY SECTOR

• 7.1. Overview
• 7.2 Public
• 7.3 Private

8. GLOBAL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 8.1. Overview
• 8.2 Distribution Partner Companies
• 8.3 Non-government Organizations (NGOs)
• 8.4 Government Authorities

9. GLOBAL PNEUMONIA VACCINE MARKET, BY GEOGRAPHY

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Rest of Europe
• 9.4. Asia Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest of Asia Pacific
• 9.5. Rest of the World
  • 9.5.1. Latin America
  • 9.5.2. Middle East & Africa

10. GLOBAL PNEUMONIA VACCINE MARKET COMPETITIVE LANDSCAPE

• 10.1. Overview
• 10.2. Company Market Ranking
• 10.3. Key Development Strategies

11. COMPANY PROFILES

• 11.1. Pfizer Inc.
  • 11.1.1. Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Outlook
  • 11.1.4. Key Developments
• 11.2. Merck & Co. Inc.
  • 11.2.1. Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Outlook
  • 11.2.4. Key Developments
• 11.3. GlaxoSmithKline plc
  • 11.3.1. Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Outlook
  • 11.3.4. Key Developments
• 11.4. AstraZeneca plc
  • 11.4.1. Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Outlook
  • 11.4.4. Key Developments
• 11.5. Sanofi Pasteur
  • 11.5.1. Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Outlook
  • 11.5.4. Key Developments
• 11.6. Serum Institute of India Pvt Ltd.
  • 11.6.1. Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Outlook
  • 11.6.4. Key Developments
• 11.7. Abbott Laboratories
  • 11.7.1. Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Outlook
  • 11.7.4. Key Developments
• 11.8. F. Hoffmann-La Roche Ltd.
  • 11.8.1. Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Outlook
  • 11.8.4. Key Developments
• 11.9. CSL Limited
  • 11.9.1. Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Outlook
  • 11.9.4. Key Developments
• 11.10. Bharat Biotech International Limited
  • 11.10.1. Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Outlook
  • 11.10.4. Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13. Appendix

• 13.1. Related Research